Covit-19 | Vietnam Cuba approves the use of the Abdala vaccine

(Havana) Vietnam, the first country to approve the emergency use of the Abdala antiviral vaccine developed in Cuba since Saturday in the wake of the rise in COVID-19 cases, is the state drug board. Biocupharma

“Based on the rigorous evaluation of the Aptala vaccine document, the Vietnamese Drug Control Authority has approved the emergency use of the Cuban Immunogen,” the group said on Twitter.

In addition to Abdala, which Venezuela has already signed a distribution agreement with, Cuba has developed the Soperana 02, which was approved in July for emergency use in Iran and Soberana Plus.

Aptala and Soperana 02, based on a reconstituted protein, have the same technique as the US company Nova Vox and the French company Sanofi, which scientists say is more than 90% effective in preventing the onset of the disease with symptoms. Cubans.

According to BioCubaFarma, Cuba began discussing their accreditation with World Health Organization (WHO) experts on Thursday.

Argentina and Mexico are interested in getting it.

The announcement comes as Vietnamese President Nguyen Xuan Phuc arrives in Cuba on Saturday for a three-day official visit and will meet with his Vice President Miguel Diaz-Canel at the La Havana Center for Genetic Engineering and Biotechnology (CIGB). Abdala is the inventor of the vaccine.

During a telephone conversation on August 23, the official newspaper, MM. Nguyen and Diaz-Canel expressed their desire to “continue to strengthen.” […] Bilateral cooperation in all fields. ”

Under US sanctions since 1962, Cuba has been developing its own vaccines since the 1980s and was the first country in Latin America to develop one against COVID-19.

See also  Migrants: Thousands in convoys leave Mexico for the United States - North America

Vietnam, hailed as a role model in the fight against the epidemic in 2020, is currently experiencing a sharp rise in pollution thanks to its strict policy of isolation and monitoring of affected populations.

Leave a Reply

Your email address will not be published. Required fields are marked *